Welcome to our dedicated page for Ionis Pharmaceuticals SEC filings (Ticker: IONS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, along with AI-powered summaries to help interpret complex documents. As a biotechnology issuer focused on RNA-targeted medicines, Ionis uses filings such as Forms 8-K, 10-Q and 10-K to report clinical milestones, regulatory events, financing transactions and operating results.
Recent Form 8-K filings illustrate how Ionis communicates material developments. The company has furnished press releases on pivotal Phase 3 CORE and CORE2 results for olezarsen in severe hypertriglyceridemia, positive pivotal data for zilganersen in Alexander disease, and FDA approval of DAWNZERA (donidalorsen) for prophylaxis to prevent attacks of hereditary angioedema. Other 8-Ks describe FDA Breakthrough Therapy designations, European regulatory opinions and key clinical readouts across neurology and cardiometabolic programs.
Ionis also uses current reports to disclose capital markets activity. One 8-K details the issuance of 0.00% Convertible Senior Notes due 2030, including the terms of the indenture, conversion mechanics, redemption provisions, events of default and use of proceeds, such as repurchasing earlier convertible notes and funding general corporate purposes. Additional filings cover quarterly financial results, where the company presents both GAAP and non-GAAP measures, and governance or contractual matters like advisory services agreements.
On this page, Stock Titan connects directly to EDGAR to surface new Ionis filings as they are posted. AI-powered summaries help explain lengthy documents, highlighting items such as clinical trial outcomes, regulatory status updates, financing terms, risk factor changes and other key disclosures. Investors can quickly locate annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and other relevant filings, and use the AI analysis to understand how each document may relate to Ionis’ RNA-targeted pipeline, marketed medicines and capital structure.
Ionis Pharmaceuticals Chief Executive Officer Brett P. Monia reported a series of option exercises and stock sales. On March 9–10, 2026, Monia exercised non-qualified stock options covering 148,454 shares of common stock at an exercise price of $60.89 per share.
Across the same two days, Monia sold 160,773 shares of common stock in open-market transactions at weighted average prices in the mid‑$70 range. These sales were made pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on December 8, 2025. Following the transactions, Monia directly owns 242,662 shares of Ionis Pharmaceuticals common stock.
Ionis Pharmaceuticals EVP Kyle Jenne exercised stock options and sold shares in a planned trade. He exercised options for 37,277 shares of Common Stock at exercise prices of $34.69 and $46.10 per share, then sold 37,277 shares in open-market transactions at weighted average prices of $75.502 and $76.30 per share.
The sales were made under a Rule 10b5-1 trading plan adopted on December 8, 2025. Following these transactions, Jenne directly holds 16,389 shares of Ionis Pharmaceuticals Common Stock.
IONS filed a Form 144 notifying proposed sales of Common Stock. The notice lists two option-exercise related lots of 4,675 and 32,602 shares scheduled on 03/10/2026 to be sold for cash. The filing also reports a prior sale of 1,823 shares on 01/16/2026 for $138,963 by Kyle Jenne.
IONS filing reports proposed sales of Common Stock by Patrick O'Neil. The document lists two transactions: 9,191 shares on 01/06/2026 for $700,602.00 and 6,179 shares on 01/30/2026 for $512,905.00. The filing also references Restricted Stock Units dated 01/15/2018 and an indicated share count of 165,190,000 as of 03/09/2026.
Ionis Pharmaceuticals announced planned changes to its Board of Directors. Long‑serving directors B. Lynne Parshall and Joseph H. Wender will retire at the end of their current terms, with the transitions effective June 4, 2026 and aligned with the 2026 Annual Meeting of Stockholders.
On the same date, Peter N. Reikes will rejoin the board as a director. He recently served as senior strategy advisor with the Advanced Research Projects Agency for Health and earlier as senior advisor to the FDA, following a long career in healthcare investment banking and prior board service at Ionis from 2018 to 2021.
Ionis Pharmaceuticals director Joseph Loscalzo reported option exercises and related share sales in early March. He exercised non-qualified stock options to receive common shares at an exercise price of $38.06 per share, then sold 1,032 common shares at weighted average prices around $80–$81.
The sales, executed on March 3–4, 2026, were carried out under a pre-established Rule 10b5-1 trading plan. After these transactions, Loscalzo directly owned 36,330 common shares of Ionis Pharmaceuticals.
Ionis Pharmaceuticals director Joseph Klein III reported mixed stock transactions involving option exercises and share sales. On March 3, 2026, he exercised non-qualified stock options into 16,000 shares of common stock at exercise prices of $40.05 and $42.88 per share, then sold 21,332 shares in open-market transactions at weighted-average prices between $78.615 and $81.025, pursuant to a Rule 10b5-1 trading plan adopted on November 25, 2025. After these trades, he held 11,014 shares directly and 100 shares were reported as held indirectly by his son, for which he disclaimed beneficial ownership.
IONIS PHARMACEUTICALS INC director Allene M. Diaz reported option exercises and share sales. On March 3, 2026, she exercised non-qualified stock options covering 40,321 shares of common stock at exercise prices of $38.06, $40.05, and $41.08 per share.
On the same date, she sold a total of 54,878 shares of common stock in open-market transactions at weighted average prices ranging from about $78.57 to $81.01, pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on November 25, 2025. Following these transactions, she directly held 3,811 shares of Ionis common stock.
Ionis Pharmaceuticals executive Shannon L. Devers, EVP and Chief Human Resources Officer, reported multiple transactions on common stock and non-qualified stock options of Ionis Pharmaceuticals Inc.
Devers exercised derivative securities and acquired common shares through option exercises, then sold 20,106 shares of common stock in open-market transactions at weighted average prices of $79.115, $79.999, and $80.837. According to the disclosure, these sales were made under a Rule 10b5-1 trading plan adopted on November 24, 2025, with individual sale prices ranging from $78.61 to $81.01. After these transactions, Devers directly owned 22,541 shares of Ionis common stock.
Ionis Pharmaceuticals executive Frank Bennett reported multiple stock transactions. On March 3, 2026, the EVP and Chief Scientific Officer exercised non-qualified stock options, receiving 16,463 common shares at an exercise price of $32.60 per share and 48,626 shares at $60.89 per share. He then sold 71,600, 12,687 and 802 common shares in open-market trades at weighted average prices of $79.099, $79.8778 and $80.762 per share, respectively, under a pre-arranged Rule 10b5-1 trading plan adopted on November 19, 2025. After these transactions, he directly owned 80,554 Ionis common shares.